Söring starts neurosurgical research project

On August 1st, Söring will start the three-year research project "UltraLas", which aims to improve tumour detection and thus enable an even more precise and low-risk resection of neurosurgical lesions. Over the next three years an interdisciplinary team from Germany will work on developing and evaluating various measurement methods for the intraoperative in vivo recognition of tumour extent, vascular architecture and tumor elasticity for neurosurgery. The main objective will be the reliable detection of tumor tissue, which is still difficult or involves great technological effort. The more reliably the edges of brain tumors can be determined, the more accurately the lesions can be resected – e.g. with Söring Micro instruments. For the patients’ health it is extremely important to remove the cancerous tissue as completely as possible and at the same time to preserve adjacent healthy brain tissue and larger blood vessels. The interdisciplinary team hopes that the new methods will increase the extent of resection, reduce the patient's risk and prolong their life. In addition to Söring, two research institutes, a laser company and the Department of Neurosurgery of the University Hospital Schleswig-Holstein (UKSH) are involved in the project, which is funded by the Federal Ministry of Education and Research (BMBF). Source: Soering GmbH Press Release from July 31st, 2018, https://www.soering.de/en/news-events/article/news/soering-starts-neurosurgical-research-project/

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …